Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amgen: We Expect To Double Biosimilar Sales By 2030

Interchangeability ‘Not Essential’ But A Differentiator; Ustekinumab Studies Continue

Executive Summary

Amgen management paid close attention to the company’s biosimilar portfolio and pipeline during several recent calls with investors, including what differentiates the firm from its rivals in the biosimilars space.

You may also be interested in...



Amgen’s Biosimilars Business Dips As Key Contributors Face Fresh Competition

Two of Amgen’s flagship biosimilar products saw a notable drop in sales in Q1 in the face of increased competition, but impending launches are expected to put the unit back on track. 

Amgen Provides Ambitious Update On Biosimilars Business

Amgen CEO Robert Bradway has delivered confident predictions for the company’s biosimilars business at the J.P. Morgan Healthcare Conference, with a steady flow of launches expected to give the company’s earnings a significant boost over the coming years.

Teva: Amgen’s Interchangeable Humira Biosimilar Too Late For January 2023

Teva discussed its proposed rivals in the US biosimilar adalimumab space, biosimilar business development plans and prioritizing debt during its Q3 earnings call. The Israeli firm’s revenues succumbed to challenges in the US generics space.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

GB151467

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel